

Transfusion use in patients with rare blood cancer (myelodysplastic syndromes)

Submission date 13/01/2020	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 24/01/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 02/09/2021	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Myelodysplastic syndrome (MDS) is a type of blood cancer that limits the body's ability to produce blood cells. Patients with MDS receive an especially large number of blood transfusions. It is well known that a significant fraction of all manufactured blood units are transfused to patients with blood disorders, such as leukemia. Many patients with MDS get very large numbers of transfusions, resulting in very large costs. However, previous studies have not been able to estimate the total costs for transfusion therapy for this patient group, and has not been able to look in detail at these costs.

In the proposed project researchers will calculate how much blood patients with MDS receive and what transfusion therapy for these patients would cost.

Who can participate?

All adult patients with a confirmed histopathological diagnosis of MDS in the time period from 2008-2017, living in Sweden.

What does the study involve?

Patient records will be analysed to estimate the costs related to blood transfusions.

What are the possible benefits and risks of participating?

None.

Where is the study run from?

Karolinska Institutet, Sweden

When is the study starting and how long is it expected to run for?

February 2020 to August 2020

Who is funding the study?

1. Celgene, USA
2. Vetenskapsrådet (Swedish Research Council, VR)

Who is the main contact?

Dr Gustaf Edgren
gustaf.edgren@ki.se

Contact information

Type(s)

Public

Contact name

Dr Gustaf Edgren

ORCID ID

<https://orcid.org/0000-0002-2198-4745>

Contact details

Department of Medicine Solna, Karolinska Institutet
Clinical Epidemiology Division T2
Karolinska University Hospital
Stockholm
Sweden
171 76
+46 708188662
gustaf.edgren@ki.se

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

1

Study information

Scientific Title

Transfusion use in patients with myelodysplastic syndromes (MDS): a nationwide, retrospective cohort study

Acronym

SCANDAT

Study objectives

The overarching aim of the study is to perform a detailed characterization of blood transfusion use -- incorporating ensuing direct and indirect costs -- for patients with myelodysplastic syndromes (MDS).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 02/05/2019 Swedish Ethical Review Authority (Etikprövningsmyndigheten, Box 2110, 750 02, Uppsala, Sweden; +46 10-475 08 00; registrator@etikprovning.se), ref: 2018/167-31 and 2019-02636

Study design

Retrospective cohort study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Myelodysplastic syndromes

Interventions

The study will include all adult patients with a confirmed histopathological diagnosis of MDS in the time period from 2010-2017, living in Sweden. In these patients, researchers will use nationwide registers to identify all blood transfusions. By incorporating known direct costs, and projected indirect costs, for transfusion therapy, researchers will estimate both blood use and the overall total costs for transfusion therapy in this patient group. Analyses will be conducted by first computing a cumulative number of transfusions per patient as a function of time since diagnosis and then the cumulative average number of transfusions for each patient by dividing this number with the corresponding number of patients who remain alive and under follow-up at the same time. Using this adjusted model, researchers can derive blood utilization estimates which incorporate both mortality, cure following aggressive treatment such as transplantation, as well as transition between risk groups. Estimates will thus be more specific for the subgroup at hand. Confidence intervals for averages can be constructed using boot strap methods. All analyses will be stratified by patient IPSSR risk group.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Total transfusion cost, incorporating both direct and indirect costs, related to blood transfusions measured using patient records

Key secondary outcome(s)

Measured using patient records:

1. Total direct cost for transfusion therapy
2. Total indirect for transfusion therapy
3. Total number of blood transfusions, overall, and divided by component type

Completion date

01/07/2020

Eligibility

Key inclusion criteria

Adult patients with a confirmed histopathological diagnosis of MDS in the time period from 2008-2017, living in Sweden

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

2858

Key exclusion criteria

Researchers will restrict the analyses to patients with known WHO-subgroup and IPSS/IPSS-R risk group respectively

Date of first enrolment

01/01/2008

Date of final enrolment

31/12/2017

Locations

Countries of recruitment

Sweden

Study participating centre

Karolinska Institutet

Box 281

Stockholms
Sweden
17177

Sponsor information

Organisation

Karolinska Institute

ROR

<https://ror.org/056d84691>

Funder(s)

Funder type

Not defined

Funder Name

Celgene

Alternative Name(s)

Celgene Corporation

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Funder Name

Vetenskapsrådet

Alternative Name(s)

Swedish Research Council, VR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Sweden

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to no IRB approval granted to share data.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		11/05/2021	02/09/2021	Yes	No
Protocol file	version v4.0		05/02/2020	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes